Search - tctmd.com

Displaying 101 - 120 of 382

Sort: Relevancy | Date

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

Ultra-Thin Strut DES: A Meaningful Advance?

Presenter: Renu Virmani, Clemens von Birgelen, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Presenter: Renu Virmani, Clemens von Birgelen, David E. Kandzari

September 22, 2018

Presentation TCT 2018

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Presenter: Renu Virmani, Clemens von Birgelen, Michael Joner

September 22, 2018

Presentation TCT 2018

TCT-64: Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Ricardo A. Costa

September 21, 2018

Presentation TCT 2018

TCT-63: Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

Presenter: Antonio L. Bartorelli, David G. Rizik, Michael Haude

September 21, 2018

Presentation TCT 2018

TCT-61: Clinical Outcomes Following Complete Bioresorption of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Four-year Results from the ABSORB III Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Dean J. Kereiakes

September 21, 2018

Presentation TCT 2018

TCT-62: Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Patrick W. Serruys

September 21, 2018

Presentation TCT 2018

What is the Future of Bioresorbable Scaffolds?

Presenter: Jeroen J. Bax, Stephan Windecker, Michael Haude

September 21, 2018

Presentation ESC 2018

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

Presenter: Holger M. Nef

August 29, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

News Daily News

Ultrathin-Strut DES Outperform Second-Gen DES at 1 Year: Meta-analysis

Caitlin E. Cox

June 28, 2018

News Conference News EuroPCR 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

Caitlin E. Cox

May 30, 2018

News Conference News EuroPCR 2018

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Michael O'Riordan

May 25, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

Podcast

Quantitative Flow Ratio, Live Cases, and More

May 09, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

Presentation ACC 2018

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Presenter: Ajay J. Kirtane

March 11, 2018

News Industry News

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

February 26, 2018

Advertisement

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Ultra-Thin Strut DES: A Meaningful Advance?

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

TCT-64: Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

TCT-63: Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

TCT-61: Clinical Outcomes Following Complete Bioresorption of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Four-year Results from the ABSORB III Trial

TCT-62: Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

What is the Future of Bioresorbable Scaffolds?

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Ultrathin-Strut DES Outperform Second-Gen DES at 1 Year: Meta-analysis

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Quantitative Flow Ratio, Live Cases, and More

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content